Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
zydus cadila
1 Vial
Bevacizumab
Keep in cold place
Delivering To:
Overview
Bevacizumab is an active component of the anticancer medicine Bryxta 400mg Injection. This medication was developed to prevent tumors from growing. It can be administered in combination with other chemotherapeutic medications to treat colorectal, lung, kidney, brain, cervical, and metastatic breast cancer. Further, it is used to treat primary peritoneal cancer, fallopian tube cancer, and ovarian cancer. Children under the age of eighteen and teens are not advised to use Bryxta 400mg Injection. Bryxta (Bevacizumab) is available in the form of injections with strengths of 100mg and 400mg.
Colorectal Cancer
The following conditions are approved for injection treatment with Bryxta 400mg: Advanced non-small-cell lung cancer. Liver Cancer- Hepatocellular carcinoma.Persistent, recurrent, or metastatic breast cancer. Metastatic cervical cancer. Advanced kidney cancer. Metastatic colorectal cancer.Glioblastoma multiforme (brain cancer). ovary, cervical, fallopian tube, or primary peritoneal cancer.
Bryxta 400mg Injection may cause some serious and unwanted side effects. This requires immediate medical attention; otherwise, it can also lead to a higher risk. Do not forget to discuss the risks and benefits of this medication with your doctor.
Bleeding gums
Chest pain
Sore throat
Fever
Dizziness
Irregular heartbeat
Loss of appetite
Body pain
Runny nose
Vomiting
Diarrhea
Seizures
Unusual bleeding
High blood pressure
Bryxta 400mg Injection will be given intravenously by your doctor or nurse. After the dilution, the infusion must be injected immediately. The 400 mg injection of bevacizumab according to recommendations by your physician. Make sure to take this injection in accordance with your dose regimen and avoid mishandling this medication. Your doctor can provide emergency medical care in the event of an overdose.
Bryxta 400mg is a a recombinant humanized monoclonal antibody is for treating a variety of advanced malignancies as a targeted therapy. It works by attaching itself specifically to the protein known as vascular endothelial growth factor A (VEGF-A), which is found in the body's blood and lymph arteries. It prohibits VEGF-A from binding with its receptors. This additionally blocks of blood vessels which supply the tumor with nutrients and oxygen. As a result, it slows the rate at which cancer progresses.
Alcohol
unsafe
While undergoing therapy with Bryxta 400mg Injection, ask your doctor if it's safe for you to drink alcohol.
Pregnancy
consult your doctor
If you are pregnant or want to become pregnant, let your doctor know before beginning Bryxta 400mg Injection medication. Lungs. Before beginning Bryxta 400mg injection medication, let your doctor know if you have any lung issues.
Breast Feeding
consult your doctor
Bryxta 400mg Injection may affect your child's growth; it is recommended to avoid breastfeeding for at least six months following your treatment.
Driving
danger
Avoid driving or using machinery while you are on your treatment with Bryxta 400mg Injection as it is related to cause dizziness or sleepiness.
Kidney
caution
Do not take Bevacizumab 400mg Injection without a doctor's consultation in case of kidney problems.
Liver
caution
To prevent any severe adverse effects, let your doctor know if you have liver illness before beginning Bryxta 400mg Injection.
Bevacizumab 400mg Injection is given by your doctor or nurse. If you miss an appointment for a scheduled dose of this medicine, contact your doctor immediately.
This infusion is used to treat a certain type of brain tumor and cancer of the kidney, colorectal, lung, ovarian, etc.
Bevacizumab injection works by blocking a protein called vascular endothelial growth factor (VEGF). This stops the formation of blood vessels.
Some common side effects of bevacizumab 400mg injection are chest pain, sore throat, dizziness, severe bleeding, high blood pressure, kidney or heart problems, loss of appetite, body pain, etc.
This medicine is given in the form of an injection, which is given by your doctor or nurse. This medication is usually given once every 2 or 3 weeks or as advised by the doctor.
After the administration, the effect of this medicine can be observed immediately.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices*—plus *special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Vaidyanathan, A., Vana, P., Joshi, N., Sourav, B., Bhargava, P., John, G., Ramaswamy, A., & Ostwal, V. (2025). Real-world evidence for comparative outcomes between innovator and biosimilar bevacizumab in advanced colorectal cancers. South Asian Journal of Cancer, 13(4), 296–299. https://doi.org/10.1055/s-0045-1804535
Kasliwal, R. S., Reddy, P., Maharaj, N., Shah, H., Nayak, M., Dhoot, D., & Jain, S. (2023). Comparison of efficacy and safety of a bevacizumab biosimilar, in combination with chemotherapies, in nonresectable metastatic colorectal cancer and advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, Phase III study. South Asian Journal of Cancer, 13(1), 66–76. https://doi.org/10.1055/s-0043-1774403
Sinha, S. D., Biswas, G.,Bheemareddy, B. R., Dubashi, B., Rangwala, R., Pandey, A. K., & Venkitaraman, R. (2023). A real-world study of safety, immunogenicity and efficacy of Bevacizumab in patients with solid malignancies: A Phase IV, post-marketing study in India. Cancer Informatics, 22, 11769351231177277. https://doi.org/10.1177/11769351231177277
